Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
The B-cell lymphoma/leukemia 2 protein (BCL-2) may help many types of cancers to evade cell death. However, identifying exactly where this is the case is a challenge. ABT-199 is a small molecule that selectively inhibits BCL-2, which is currently in clinical trials in lymphoid malignancies. While in...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054876/ |